Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Myriad Genetics Inc

MYD
Current price
14.7 EUR 0 EUR (0.00%)
Last closed 14.8 EUR
Company myriad.com
ISIN US62855J1043
Sector Healthcare
Industry Diagnostics & Research
Exchange Frankfurt Exchange
Capitalization 1 496 303 289 EUR
Yield for 12 month -8.13 %
1Y
3Y
5Y
10Y
15Y
MYD
21.11.2021 - 28.11.2021

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.69 EUR

P/E ratio

Dividend Yield

Current Year

+714 306 258 EUR

Last Year

+643 368 781 EUR

Current Quarter

+200 578 563 EUR

Last Quarter

+191 758 796 EUR

Current Year

+490 303 154 EUR

Last Year

+451 799 657 EUR

Current Quarter

+139 504 050 EUR

Last Quarter

+130 494 611 EUR

Key Figures MYD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -41 137 987 EUR
Operating Margin TTM -8.35 %
PE Ratio
Return On Assets TTM -5.35 %
PEG Ratio 1.4553
Return On Equity TTM -16.4 %
Wall Street Target Price 28.69 EUR
Revenue TTM 832 463 050 EUR
Book Value 8.13 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 11.2 %
Dividend Yield
Gross Profit TTM 481 526 708 EUR
Earnings per share -1.66 EUR
Diluted Eps TTM -1.66 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -14.09 %

Dividend Analytics MYD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History MYD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation MYD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 476.1905
Enterprise Value Revenue 2.0284
Price Sales TTM 1.7974
Enterprise Value EBITDA -21.816
Price Book MRQ 2.158

Financials MYD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators MYD

For 52 weeks

15.57 EUR 26.08 EUR
50 Day MA 22.63 EUR
Shares Short Prior Month
200 Day MA 22.05 EUR
Short Ratio
Shares Short
Short Percent